ArticleOncoTargets and therapy2021
Immunotherapy-Related Cystitis: Case Report and Review of the Literature.
Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Sintilimab‑related cystitis/ureteritis in high‑grade endometrial stromal sarcoma: A case report and structured literature review.Human vaccines & immunotherapeutics · 2026Review
- Non-bacterial cystitis following treatment with toripalimab for alpha-fetoprotein-producing gastric adenocarcinoma: a case report.Frontiers in immunology · 2026Article
- PD-1/PD-L1 inhibitor-related cystitis: clinical features, diagnostic exclusion, and outcomes in one definite and seven probable cases with an updated literature review.Frontiers in oncology · 2026Article
- Immune-Related Cystitis Following Immune Checkpoint Inhibitor Therapy: A Report of Two Cases.Case reports in medicine · 2026Article
- Immunotherapy-related cystitis induced by nivolumab: A case report and review of the literature.Urology case reports · 2025Article
- Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature.Frontiers in immunology · 2024Review
- Case reports of immune-related cystitis and the antibody combination hypothesis.Immunotherapy · 2024Article
- [Immune Checkpoint Inhibitors Related Cystoureteritis: A Case Report and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Review
- Successful treatment of immune-related cystitis with bladder hydrodistension.IJU case reports · 2023Article
- A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab.IJU case reports · 2022Article
- Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- Bladder rupture after pembrolizumab immunotherapy for bladder cancer: a case report.The Pan African medical journal · 2022Article
- Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review.Frontiers in immunology · 2022Review
- Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events.Frontiers in oncology · 2021Article
- Prolonged survival of thoracic SMARCA4-deficient undifferentiated tumor with immune-related cystitis: a case report and literature review.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) including anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) and anti-programmed death cell protein 1 (anti-PD1) have extended patient survival benefit and revolutionized cancer treatment. As ICIs rely on immune regeneration to eliminate tumor cells, they can also lead to an imbalance of immune reactions often called immune-related adverse events (irAEs). Rare irAEs such as ocular or cardiac toxicity or vasculitis are seen in less than 1% of patients receiving ICIs. Immune-related cystitis remains a rare occurrence. Herein, we describe a patient with extensive-stage small cell lung cancer (SCLC) and a history of syphilis with a complete response to second-line treatment using nivolumab plus paclitaxel who complained of urinary irritation symptoms. At biopsy, we found infiltration of CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.